Clinical Scorecard: Targeted NGS Streamlines Myeloproliferative Neoplasm Diagnostics

At a Glance

Key Highlights

• NGS reveals driver, co-mutation, and resistance profiles that inform prognosis and therapy.
• 90% of MPNs carry mutations in JAK2, CALR, or MPL.
• NCCN guidelines recommend NGS for diagnostic and prognostic evaluation of MPNs.
• NGS can uncover co-mutations with significant prognostic implications.
• Sequential PCR testing may miss important co-mutations.

Guideline-Based Recommendations

Diagnosis

• Use NGS panels for comprehensive genomic assessment in MPN diagnostics.

Management

• Incorporate findings from NGS into treatment planning for precision-based management.

Monitoring & Follow-up

• Monitor for co-mutations that may affect prognosis and treatment options.

Risks

• Relying solely on PCR may lead to missed diagnoses and inappropriate treatment strategies.

Patient & Prescribing Data

Patients with MPNs, particularly those with atypical or compound mutations.

IDH inhibitors may be considered for patients with IDH2 mutations.

Clinical Best Practices

• Utilize a diagnostic algorithm integrating both NGS and PCR.
• Consider NGS for patients with low variant allele frequency in driver genes.
• Assess for co-mutations that may influence prognosis and treatment.

References

• NCCN Guidelines